2026-01-12 - Analysis Report
### 1. Company Overview
Natera Inc (NTRA) is a healthcare technology company focusing on non-invasive genetic tests.

### 2. Stock Performance Comparison
- Cumulative return of NTRA: **131.61%**
- Cumulative return of S&P 500 (VOO): **94.03%**
- Divergence: **37.58**

### 3. Stock Performance Analysis
The NTRA has a divergent return rate from S&P 500, with its cumulative return outperforming the index by 37.58. This stock's return rate fluctuates, which might impact long-term investments.

### 4. Recent Stock Price Fluctuation
- Latest stock price: **$234.31**
- Last-market: **-2.19%** change
- 5-day moving average: **$242.89**
- 20-day moving average: **$233.74**
- 60-day moving average: **$218.39**
The stock price declined 2.19% in the last market session. The 5-day moving average is higher than the current price, indicating a potential rebound if it surpasses the 5-day average within the next few days.

### 5. RSI and PPO Indicators Analysis
- Market risk indicator (MRI): **0.70**
- Relative strength index (RSI): **57.54**
- Price percentage oscillator (PPO) index: **-0.03**
- Hybrid signal: Buy
- Relative divergence change: **0.90** (improving)
- 7-day Rank change: **3** (rank up)
- 7-day Dynamic expected return change: **1.90** (improving)
- Expected Return: **-43.20%**
The hybrid signal is 'Buy', and the risk level is 'Medium' as indicated by the market risk indicator of 0.70. The RSI and PPO indices indicate a relatively stable current market position of NTRA, which shows improving dynamics on some recent indicators, but this could be considered risky as the 7-day dynamic expected return is showing an improving figure.

### 6. Recent News and Significant Events
The recent news indicates various significant updates on the stock.

- The billionaire Stanley Druckenmiller is betting $1.2 billion in NTRA.
- Citigroup initiates a Buy rating on NTRA with a price target of $300.
- Natera recently announced the publication of findings from a randomized, phase III CALGB (Alliance)/SWOG 80702 study.

### 7. Analyst Opinions
- Analyst consensus rating: **Strong_Buy** (1.45, mean rating of 1-5)
- Analyst opinions: **20**
- Target price: **$256.95** (average), **$300.00** (high), **$186.00** (low)
Analysts are generally optimistic about NTRA, with a consensus rating of Strong_Buy and an average target price of $256.95.

### 8. Recent Earnings Analysis
| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-11-07 | **-0.64** | **$0.59B** |
| 2025-08-08 | **-0.74** | **$0.55B** |
| 2025-05-09 | **-0.5** | **$0.50B** |
| 2024-11-12 | **-0.26** | **$0.44B** |
| 2025-11-07 | **-0.26** | **$0.44B** |
The NTRA stock has shown declining earnings per share (EPS) in each of the given quarters, ranging from -0.5 to -0.74.

### 9. Revenue and Profitability Analysis
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | **$0.59B** | **64.91%** |
| 2025-06-30 | **$0.55B** | **63.41%** |
| 2025-03-31 | **$0.50B** | **63.12%** |
| 2024-12-31 | **$0.48B** | **62.94%** |
| 2024-09-30 | **$0.44B** | **61.79%** |
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | **$1.25B** | **-6.99%** |
| 2025-06-30 | **$1.25B** | **-8.10%** |
| 2025-03-31 | **$1.24B** | **-5.40%** |
| 2024-12-31 | **$1.20B** | **-4.50%** |
| 2024-09-30 | **$0.88B** | **-3.60%** |
Revenue and profit margins have been steadily increasing, but there has been a decline in return on equity. The net results show some improvements in profitability over the given periods.

### 10. Comprehensive Analysis (Summary of previous items)
Based on the previous analysis, the company's performance has shown a divergent trend from the S&P 500, but a Buy signal has been triggered. The RSI, PPO, and hybrid signals provide positive signals, with some relative improvements in recent dynamics. However, it seems Natera could be considered more of a high-risk medium investment for its potential due to the recent changes in expected returns, with expected returns in the negative (-43.2%). Analysts are optimistic, recommending a **Strong Buy** with a $300 price target. The recent fluctuations indicate a decline, but the long-term investment could still have potential, with revenue and profit margins showing positive signs in the provided data.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.